The management of multiple sclerosis in children: A European view

Angelo Ghezzi, Brenda Banwell, Alexey Boyko, Maria Pia Amato, Banu Anlar, Morten Blinkenberg, Maartje Boon, Massimo Filippi, Sergiusz Jozwiak, Immy Ketelslegers, Barbara Kornek, Lim Ming Lim, Eva Lindstrom, Congor Nadj, Rinze Neuteboom, Maria A. Rocca, Kevin Rostasy, Marc Tardieu, Evangeline Wassmer, Coriene Catsman-BerrevoetsRogier Hintzen

Research output: Contribution to journalArticlepeer-review


About 3-5% of all patients with multiple sclerosis experience the onset of their disease under the age of 16. A significant proportion of paediatric multiple sclerosis patients develop significant cognitive disturbances and persistent physical disability. The high relapse rate and the morbidity in the paediatric multiple sclerosis population has triggered the use of disease-modifying therapies that have been shown to reduce relapse rate, disease progression and cognitive decline in adult patients with multiple sclerosis. Hard evidence for the right treatment and its appropriate timing is scarce in paediatric multiple sclerosis. Nevertheless, expertise in this field has grown thanks to recent open-label trials and experience generated in specialized centres. In spring 2009, a first meeting was held in Rotterdam with clinicians from 11 European countries (one from Canada) that are all active in the management of paediatric multiple sclerosis. One of the aims was to generate a common view on the management of paediatric multiple sclerosis patients. The result of this meeting is presented here to help standardize treatment and to support clinicians with less experience in this field.

Original languageEnglish
Pages (from-to)1258-1267
Number of pages10
JournalMultiple Sclerosis Journal
Issue number10
Publication statusPublished - Oct 2010


  • children
  • clinically isolated syndrome
  • immunomodulatory treatment
  • MRI
  • MS
  • paediatric

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'The management of multiple sclerosis in children: A European view'. Together they form a unique fingerprint.

Cite this